Shaanxi Mikeott Technology Co., Ltd. (hereinafter referred to as "Mikeott") was established in Xi'an in January 2007 and has completed the layout of Xi'an, Suzhou, Beijing, Shanghai, Hong Kong and the United States. The company is an innovative pharmaceutical technology enterprise focusing on the research and development of new drugs, committed to becoming a global leading frontier enterprise in the research and development of bifunctional and multifunctional specific polypeptide drugs, and focused on the research and development of new drugs for cardiovascular and cerebrovascular diseases, metabolic diseases, inflammation and pain related diseases. The company is committed to creating new drugs, saving lives, meeting unsatisfied clinical needs, and protecting human health with technological innovation.

The company has established a technology platform of double specific polypeptide. The company is the initiator, implementer, verifier and developer of the concept of bispecific polypeptide, is one of the best platforms for the research and development of polypeptide drugs, and has a unique mechanism for screening multi target polypeptide drugs. The company has a national research platform for long-acting slow release of polypeptide and protein drugs, has established a research laboratory for long-acting slow release and controlled release of polypeptide drugs, and is expanding the platform for macromolecular biological drugs and nucleic acid drugs. The company has the platform type R&D capability to develop First in class and Best in class varieties.

The company has established an industrial chain including 20 new drug varieties. Up to now, there are 7 core innovative drugs in clinical and preclinical research and development, of which 3 are in the clinical research stage, 4 are in the clinical application (IND) stage in China and the United States, and others are in the research and development stage. The company has a very rich R&D pipeline. The pipeline covers five major categories of diseases, including ischemic heart disease, stroke, antithrombotic, anti-inflammatory and analgesic. R&D projects have been selected into the national "major new drug development" project for two consecutive times, and have received 25 million yuan of funding. All projects are being scientifically and orderly organized, and innovation and discovery projects are constantly entering the enterprise R&D pipeline, which has built a strong competitive development capability.

The company has established a new drug research and development consortium for nervous system with Johns Hopkins University School of Medicine, which has been ranked among the best in the United States for 20 consecutive years, and has successfully screened several effective compounds. It has established extensive cooperative relations with domestic first-class universities, research institutes and R&D enterprises to promote all-round development.

With a high sense of mission and professional level, Dr. Wang Bing, the founder of the company, is persistent and enterprising, and has established a professional technical team with international level and global vision, including 20 scientists and clinical medical experts, serving the whole process of discovery, screening, development, clinical, production, etc. of multifunctional peptide drugs. For each R&D project, the team strives for excellence and is serious and pragmatic. It is a learning professional team with strong combat effectiveness.

With the strategy of innovative drug R&D in the global pharmaceutical industry, the company has built a multi center R&D and production base starting from Xi'an, Beijing and Suzhou, with a comprehensive layout and a full chain connection. Now it has a pilot line for peptide raw material production and peptide purification of more than 1kg; A freeze-dried preparation production line can be used for pilot scale study of freeze-dried preparations with multiple specifications; A pilot scale production line based on microsphere for long-term release of polypeptide, which can be used for research and development of multi standard microsphere products; The company will build a modern R&D center and GMP production base in Suzhou to meet the development needs of the enterprise.

With the efforts of all employees of Meggitt, we hope to become the global leader in innovative peptide drugs, the world's first in peptide new drug segmentation, and the first in cardiovascular and cerebrovascular innovative drugs in China, making greater contributions to human health!